EXACT Sciences Co. (NASDAQ:EXAS) insider Graham Peter Lidgard sold 45,770 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $58.27, for a total transaction of $2,667,017.90. Following the sale, the insider now owns 237,820 shares of the company’s stock, valued at $13,857,771.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Graham Peter Lidgard also recently made the following trade(s):
- On Wednesday, November 1st, Graham Peter Lidgard sold 45,775 shares of EXACT Sciences stock. The stock was sold at an average price of $53.60, for a total transaction of $2,453,540.00.
- On Monday, October 2nd, Graham Peter Lidgard sold 81,025 shares of EXACT Sciences stock. The stock was sold at an average price of $47.16, for a total transaction of $3,821,139.00.
- On Tuesday, September 5th, Graham Peter Lidgard sold 75,683 shares of EXACT Sciences stock. The stock was sold at an average price of $40.81, for a total transaction of $3,088,623.23.
Shares of EXACT Sciences Co. (EXAS) opened at $53.50 on Wednesday. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01. EXACT Sciences Co. has a 1 year low of $13.05 and a 1 year high of $63.60.
EXACT Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.07. EXACT Sciences had a negative net margin of 60.71% and a negative return on equity of 30.32%. The company had revenue of $72.60 million during the quarter, compared to the consensus estimate of $65.03 million. During the same period in the previous year, the business earned ($0.36) earnings per share. The firm’s quarterly revenue was up 158.4% on a year-over-year basis. equities analysts expect that EXACT Sciences Co. will post -1.12 EPS for the current fiscal year.
Several equities research analysts have issued reports on EXAS shares. Bank of America set a $56.00 price objective on shares of EXACT Sciences and gave the stock a “buy” rating in a research report on Thursday, October 19th. BidaskClub upgraded shares of EXACT Sciences from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 25th. Canaccord Genuity restated a “buy” rating and set a $45.00 price objective on shares of EXACT Sciences in a research report on Thursday, September 7th. Leerink Swann restated an “outperform” rating and set a $67.00 price objective (up from $63.00) on shares of EXACT Sciences in a research report on Monday, November 13th. Finally, Robert W. Baird downgraded shares of EXACT Sciences from an “outperform” rating to a “neutral” rating and set a $56.00 price objective for the company. in a research report on Monday, November 13th. Eight investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $50.58.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State of Wisconsin Investment Board acquired a new stake in shares of EXACT Sciences in the second quarter valued at approximately $3,006,000. Victory Capital Management Inc. acquired a new stake in shares of EXACT Sciences in the second quarter valued at approximately $29,450,000. Eagle Asset Management Inc. raised its position in shares of EXACT Sciences by 19.6% in the second quarter. Eagle Asset Management Inc. now owns 1,857,185 shares of the medical research company’s stock valued at $65,688,000 after buying an additional 304,598 shares in the last quarter. Chicago Equity Partners LLC acquired a new stake in shares of EXACT Sciences in the third quarter valued at approximately $2,312,000. Finally, Bank of Nova Scotia acquired a new stake in shares of EXACT Sciences in the second quarter valued at approximately $1,482,000. Institutional investors own 82.39% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Graham Peter Lidgard Sells 45,770 Shares of EXACT Sciences Co. (EXAS) Stock” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://ledgergazette.com/2017/12/06/graham-peter-lidgard-sells-45770-shares-of-exact-sciences-co-exas-stock.html.
About EXACT Sciences
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences Co. and related companies with MarketBeat.com's FREE daily email newsletter.